Long‐Term Outcomes in Stiff Person Spectrum Disorder
European Journal of Neurology · 2026
DOI: 10.1111/ene.70609 ↗At a glance
Journal article in European Journal of Neurology, 2026. Written by Georgios Mangioris and 7 co-authors. Institution: Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA. Major MEDLINE topics: Stiff-Person Syndrome. Cited 1 times so far (Crossref); 22 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NINDS NIH HHS.
Abstract (original language)
Background
Long‐term outcome data for stiff person spectrum disorder (SPSD) remain limited and sustained response to treatment varies.
Methods
In this retrospective cohort study, we included patients with probable or definite SPSD (Mayo Clinic criteria), evaluated at Mayo Clinic (12/1995‐07/2024) with ≥ 5 years of follow‐up after diagnosis. Primary outcome measures included the modified Rankin scale (mRS) and use of gait aids.
Results
Fifty‐four patients were included, 41 (76%) were female; median age at onset was 45 years (16–78). Most were antibody‐positive (51 [94%]), with high‐titer (serum, ≥ 20 nmol/L) GAD65‐IgG in 45 (83%). Nine patients had a stiff‐limb presentation (17%). The median interval from onset to diagnosis was 2 years (0–34), and median follow‐up was 9 years (5–26). Most patients (46 [85%]) received immune therapy; 37 (82%) reported improvement. All patients had significant impairment (mRS ≥ 2) at nadir, with 31 (57%) losing functional independence (mRS ≥ 3) and 40 (75%) requiring bilateral gait assistance. The median time from onset to nadir was 6 years (0–39). At last follow‐up, most (37 [69%]) were functionally independent (mRS ≤ 2), including 8 (15%) with minimal restrictions (mRS ≤ 1). Bilateral gait assistance was needed in 22 (41%). Among 40 patients with ≥ 10 years of follow‐up, 22 (56%) had an mRS ≤ 2 and 25 (63%) required a gait aid at last follow‐up. Poor outcome in this population was associated with bilateral gait assistance at nadir and older age ( p < 0.05).
Conclusions
Although over half of SPSD patients lose functional independence at disease nadir, many regain independence and achieve well‐controlled symptoms.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
- Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
- Center for Multiple Sclerosis & Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
- Division of Neurology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
ORCID profiles: Nisa Vorasoot, Anastasia Zekeridou
Funding
- NINDS NIH HHS
Cite
APA
Mangioris, G., McKeon, A., Bower, J. H., Vorasoot, N., Dubey, D., Flanagan, E. P., Pittock, S. J., & Zekeridou, A. (2026). Long‐Term Outcomes in Stiff Person Spectrum Disorder. European Journal of Neurology. https://doi.org/10.1111/ene.70609
Vancouver
Mangioris G, McKeon A, Bower JH, Vorasoot N, Dubey D, Flanagan EP, et al. Long‐Term Outcomes in Stiff Person Spectrum Disorder. European Journal of Neurology. 2026. doi:10.1111/ene.70609
BibTeX
@article{Mangioris2026,
author = {Mangioris, Georgios and McKeon, Andrew and Bower, James H and Vorasoot, Nisa and Dubey, Divyanshu and Flanagan, Eoin P and Pittock, Sean J and Zekeridou, Anastasia},
title = {Long‐Term Outcomes in Stiff Person Spectrum Disorder},
journal = {European Journal of Neurology},
year = {2026},
doi = {10.1111/ene.70609}
}
EUVIMED